

[26 November, 2001]

RAJYA SABHA

detect at least 70% of such cases. Revised National TB Control Programme (RNTCP), using WHO recommended DOTS strategy, is being implemented in the country in a phased manner. Coverage has increased from about 20 million in end 1998 to about 440 million population at present. It is envisaged to cover 500 million population by 2002 and 800 million population by 2004. The project Districts have reported a cure rate of about 80% which means that 8 out of every 10 patients diagnosed and put on treatment under the revised strategy are successfully treated as against 4 out of 10 in the conventional programme.

(d) About 5.80 lac TB cases have been reported under the National TB Control Programme during the last six months.

Raid on Bhagirath Place Drug Market

777. SHRI AMAR SINGH:

SHRI MUNAWAR HASAN:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that during the recent raid by the Government of N.C.T. of Delhi more than 90 per cent of the medicines at Bhagirath Place, Delhi which is North India's largest wholesale drug market, have been found UD* be spurious;

(b) if so, the names of the companies whose drugs have been found spurious;

(c) the action Government have taken against them; and

(d) the steps being taken by Government to check sale of spurious drugs?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. C.P. THAKUR): (a) There was a news report to this effect which appeared in the print media on 25th October, 2001. As per the feedback available from the Drugs Control Administration, Govt, of NCT Delhi, the number of samples reported in the news items to be spurious were actually the unclaimed drugs recovered from unlicensed godowns in an isolated case. Thus this figures does not represent either the Bhagirath Place Market or Delhi.

(b) As per the feedback available from the Drugs Control Administration, Government of NCT Delhi a statement indicating the name of companies whose

names were printed on the labels of the seized drugs found to be spurious because of disowning by the original manufacturers is annexed. (*See below.*)

(c) As per the feedback available from the Drugs Control Administration Government of NCT, Delhi, the Delhi Police has launched prosecution against the erring persons involved in the racket.

(d) Since manufacture and sale of spurious medicines is a clandestine activity indulged in by anti-social persons steps are taken from time to time by the enforcement authorities of the States to detect and unearth spurious take drugs in the inter-state commerce.

I. The Drugs Controller General (India) has advised the state drug controllers to take the following measures for curbing the incidence of spurious drugs:—

- (a) Constitution reactivation of State Drug Advisory Committees in which various trade and industry associations as well as consumer associations should find representation.
- (b) Establishment of separate intelligence-cum-legal machinery with police assistance Training should be provided to selected officials of Drug Control Administration in the modalities of intelligence work, prosecution etc. in respect of spurious counterfeit drugs.
- (c) To ensure speedy analysis of drug samples by establishing own state level drug testing facilities.
- (d) State Drugs Control Authorities should be cautious while approving licences for drug products to ensure that look-alike products are not encouraged.
- (e) To develop efficient communication facilities and recall procedures.
- (f) Surveillance of suspected dealers.
- (g) Engaging experienced counsel for fighting spurious drug cases.
- (h) Cooperation of Pharmaceutical industry by regular interaction with them.

II. Union Minister of Health and Family Welfare had specifically taken up the issue of combating the menace of manufacture and sale of spurious, adulterated and counterfeit drugs in the meeting of Central Council of Health and Family Welfare held on 12th and 13th July, 2001 in New Delhi.

It was resolved that in order to address issues relating to the increasing reports of the spurious counterfeit drugs, special attention requires to be given to monitor and unearth such illegal activities by Constituting a separate intelligence cell in the respective drugs control organization and in seeking cooperation of the Pharma Industry the trade.

- 111.** Union Ministry of Health and Family Welfare has constituted a Committee under the Chairmanship of DGHS on July 18, 2001 associating members from industry, trade, drug regulatory officials and public representative to go into all aspects of the menace of spurious drugs and suggest remedial measures.

Statement

Details of 49 Drugs Declared as spurious by the Original Manufacturer

S.No.	Mfg. By	Name of Drug	B.NO
1.	Alembic Limited	Nimegesic	91843
2.	Alkem Laboratories Ltd.	Alcipro 500	ACIMO 219N
3.	Alkem Laboratories Ltd.	Derbac Cream	AH05
4.	Alkem Laboratories Ltd.	Formin-850	FRTF0006
5.	Alkem Laboratories Ltd.	Sumo	0079
6.	Aristro Pharmaceuticals Limited	Cefadrox Ktab 250 MG	45H030
7.	Aristro Pharmaceuticals Limited	Megaphen Caps	57 J099
8.	Astra CFL Pharma Limited	Jectofer	JPM510
9.	Blue Cross Laboratories Limited	MeftaLSPS	YMS042
10.	Cadila Pharmaceuticals Ltd.	Acilocl50	0179
11.	Cadila Pharmaceuticals Ltd.	Olit-20	0020
12.	Cipla Ltd.	Ciplox-250	Y91203
13.	Dabur India Limited	Ulzol-20	0025
14.	Dr. Reddy Laboratories Ltd.	NiseTab	B0055
15.	Duphar-Interfran Ltd.	Duphaston	LJ3176
16.	Elder Pharmaceuticals Ltd.	Shelcal-500	13901
17.	Emcure Pharmaceuticals Ltd.	Ferium	CFT011
18.	Fulford (India) Limited	Quadiderm Cream	66699
19.	Glaxo India Limited	Phexin Caps-500MG	M135
20.	Glaxo India Limited	Zinetac-150	NE606

S.No	Mfg. By	Name of Drug	B.NO
21.	Hoechst Marion Roussel Limited	Combiflam	210264
22.	IPCA Laboratories Limited	Perinom	0014GDF
23.	IPCA Laboratories Limited	Tenolol 50	7062HDF
24.	Kopran Limited	ATEN-50	S05I9245
25.	Lupin Laboratories Ltd.	Pyzina-750	9068
26.	NBZ Pharma Ltd.	Inj.M.V.I.	NP0177
27.	Novartis India Limited	Methergin	9Y010G
28.	Novartis India Limited	Syniocinon 51 U	07023G
29.	Novartis India Limited	VoveranSR-100	13045 V
30.	Parke-Davis (India) Limited	ChIormycetin-250	111
31.	Pfizer Limited	Dolonex-DT	020-04105L
32.	Pfizer Limited	Oxytetra Caps 500 MG	020-51257L
33.	Pfizer Limited	Oxytetra caps 500MG(A)	020-51183
34.	Phone-Poulenc (India) Limited	Ciprofloxacin 500	144
35.	Rhone-Poulenc (India) Limited	Rovamycin Forte	112
36.	Rhone-Poulenc (India) Limited	Rovamycin Forte	104
37.	Sarabhai Piramai Pharmaceuticals Pvt. Ltd.	Esgipyrim	9J136
38.	Sarabhai Piramai Pharmaceuticals Pvt. Ltd.	Estipyrim	0D1035
39.	Smithkline Beecham Consumer Healthcare Ltd.	Crocin	0100
40.	Smithkline Beecham Consumer Healthcare Ltd.	Crocin	S9238
41.	Smithkline Beecham Pharmaceuticals (I) Ltd.	Zental	0006
42.	Torrent Pharmaceuticals Ltd.	Alprax-0.25	1004036
43.	Torrent Pharmaceuticals Ltd.	Alprax-0.25	1012132
44.	Torrent Pharmaceuticals Ltd.	Domastal	1010050
45.	Uni Sankyo Ltd.	Sporlac	1419
46.	Unichem Laboratories Ltd.	Ampoxin-500	B9I040
47.	Zydus Cadila	Ciprobid-500	ZH9028
48.	Zydus Cadila	Ocid-20	1018
49.	Zydus Cadila	Neuroxin-12	1.9170